Stockscreener 앱 받기
18.29
0.83%
0.15
전일 마감가:
$18.14
열려 있는:
$18.09
하루 거래량:
970.80K
Relative Volume:
0.82
시가총액:
$572.29M
수익:
-
순이익/손실:
$-69.47M
주가수익비율:
-3.2676
EPS:
-5.5973
순현금흐름:
$-73.92M
1주 성능:
+23.00%
1개월 성능:
+9.52%
6개월 성능:
-48.03%
1년 성능:
-18.35%
1일 변동 폭
$17.28
$18.39
1주일 범위
$14.43
$19.23
52주 변동 폭
$14.43
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
명칭
Lenz Therapeutics Inc
전화
858-925-7000
주소
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
LENZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
18.29 | 567.60M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2025-03-18 | 개시 | TD Cowen | Buy |
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-04-10 | 개시 | Citigroup | Buy |
| 2024-03-27 | 개시 | Piper Sandler | Overweight |
| 2023-02-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-25 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-01-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-14 | 개시 | BTIG Research | Buy |
| 2022-03-22 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | 개시 | Morgan Stanley | Overweight |
| 2021-07-20 | 개시 | SVB Leerink | Outperform |
모두보기
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc.LENZ - Your Wyoming Link
LENZ Therapeutics (NASDAQ:LENZ) Trading Up 9.5%Should You Buy? - MarketBeat
Lenz Therapeutics launch of "Make It Vizzable" with Sarah Jessica Parker as a brand ambassador - marketscreener.com
LENZ Therapeutics and Sarah Jessica Parker announce the launch of 'Make it VIZZable”, the VIZZ consumer campaign - The Manila Times
LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign - PR Newswire
Sarah Jessica Parker Reveals the Health Issue That Almost Got in the Way of Her Favorite Pastime (Exclusive) - People.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ ... - Bluefield Daily Telegraph
Market Review: Will LENZ Therapeutics Inc stock continue upward momentumMarket Trend Review & Weekly Setup with ROI Potential - Bộ Nội Vụ
Shorts Report: How LENZ Therapeutics Inc stock reacts to global recession fearsTake Profit & Fast Exit Strategy with Risk Control - moha.gov.vn
A Look At LENZ Therapeutics (LENZ) Valuation After VIZZ Launch Momentum And New Lunatus Agreement - Yahoo Finance
Published on: 2026-01-12 22:19:01 - Улправда
Aug Momentum: Will LENZ Therapeutics Inc outperform its industry peers2025 Key Lessons & Real-Time Stock Price Movement Reports - baoquankhu1.vn
LENZ Therapeutics (LENZ) Is Down 7.1% After VIZZ Middle East Deal And Early Launch DataHas The Bull Case Changed? - Yahoo Finance
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
How sustainable is LENZ Therapeutics Inc. stock dividend payoutJuly 2025 Opening Moves & Long Hold Capital Preservation Tips - Улправда
Will LENZ Therapeutics Inc. stock see insider buyingJuly 2025 Short Interest & Accurate Intraday Trading Signals - Улправда
FOMO Trade: Why LENZ Therapeutics Inc. stock is recommended by analysts2025 Trading Volume Trends & Technical Pattern Based Signals - moha.gov.vn
LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Exploring a Potential 245% Upside in the Biotechnology Sector - DirectorsTalk Interviews
LENZ Therapeutics Reports Preliminary Q4 2025 Results, Highlights VIZZ Launch - VisionMonday.com
Can LENZ Therapeutics Inc. stock reach $100 price targetJuly 2025 Patterns & Real-Time Buy Signal Alerts - ulpravda.ru
LENZ Therapeutics (NASDAQ:LENZ) Sets New 52-Week LowHere's Why - MarketBeat
Why LENZ Therapeutics Inc. stock is recommended by analystsTrade Risk Assessment & Community Verified Trade Alerts - ulpravda.ru
Why LENZ Therapeutics Inc. stock could outperform in 2025Analyst Upgrade & Risk Controlled Stock Pick Alerts - ulpravda.ru
Why LENZ Therapeutics Inc. stock is popular among millennialsJuly 2025 Selloffs & Daily Oversold Bounce Ideas - Улправда
Analysts Expect Breakeven For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Before Long - Yahoo Finance
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates - The Manila Times
LENZ Therapeutics Reports Strong Initial Sales and Prescription Volume for VIZZ™ after Launch for Presbyopia Treatment - Quiver Quantitative
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Lenz, Lunatus announce exclusive partnership for VIZZ in Middle East - Yahoo Finance
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ in the Middle East - marketscreener.com
LENZ Therapeutics and Lunatus Ink Exclusive Commercialization Partnership for VIZZ in Middle East - VisionMonday.com
Lenz Therapeutics and Lunatus announce partnership for Vizz(TM) - marketscreener.com
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East - The Manila Times
FDA-approved presbyopia eye drop VIZZ to reach Middle East - Stock Titan
LENZ Therapeutics responds to FDA adverse event report - MSN
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year LowWhat's Next? - MarketBeat
Is LENZ Therapeutics Inc a good long term investmentConsumer Goods Stocks & Free Stay Informed With Forecasts - earlytimes.in
Aug Mood: Why LENZ Therapeutics Inc stock is recommended by analystsQuarterly Profit Summary & Expert Approved Trade Ideas - moha.gov.vn
LENZ Therapeutics (LENZ) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 5.1%Time to Sell? - MarketBeat
Lenz plunges after adverse event report on eye therapy - MSN
How LENZ Therapeutics Inc. stock compares to industry benchmarksPortfolio Growth Summary & Growth Focused Investment Plans - Улправда
Is LENZ Therapeutics Inc. stock trading near support levels2025 Institutional Moves & Technical Pattern Recognition Alerts - ulpravda.ru
Lenz Therapeutics Inc (LENZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lenz Therapeutics Inc 주식 (LENZ) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Sale |
26.10 |
10,000 |
261,022 |
4,733 |
4.73%
0.92%
자본화:
|
볼륨(24시간):